NCT04520659View on ClinicalTrials.gov

Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age

PHASE1CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

March 16, 2022

Primary Completion Date

April 18, 2024

Study Completion Date

April 18, 2024

Conditions
RSV Infection
Interventions
BIOLOGICAL

RSV LID/ΔM2-2/1030s

10\^5 plaque-forming units (PFU); administered as nose drops

BIOLOGICAL

Placebo

Administered as nose drops

Trial Locations (3)

14642

University of Rochester Medical Center, Rochester

21205

John Hopkins Bloomberg School of Public Health, Baltimore

37232

Vanderbilt University, Nashville

All Listed Sponsors
collaborator

Sanofi Pasteur, a Sanofi Company

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH